Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

AZ’s Tagrisso beats chemotherapy in lung cancer trial

Phase III data shows greater progression-free survival in mutation-positive NSCLC patients

- PMLiVE

Pfizer gets record £84m fine for hiking price of epilepsy drug

US firm plans to appeal after CMA finds it raised NHS fee by 2,600% in 2012

Understanding the chronic disease patient journey in emerging markets

In this paper, we will explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these...

Inizio

Infographic: Keeping tracking on track

Our best practice approach to tracking studies.

Inizio

- PMLiVE

Stephanie Marchesi joins WE Communications

Becomes president of agency’s US health business and East Coast presence

- PMLiVE

Lucid Group kick off their Winter Festival

The start of December not only signalled the official calendar countdown to Christmas, but also marked the official launch of the Lucid Winter Festival, which culminates in the Winter Summit...

Lucid Group Communications Limited

- PMLiVE

Keytruda closes in on Opdivo’s lead in Hodgkin lymphoma

KEYNOTE-087 trial shows an overall response rate of 69 percent

What does the Five Year Forward View mean for pharma?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.

Wilmington Healthcare

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

Walgreens to show drug efficacy reports from PatientsLikeMe

Will also show alternative choices of medication

- PMLiVE

Aurora appoints Siân Hurst as managing director

Healthcare agency’s founders Neil Crump and Claire Eldridge move to CEO roles

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links